Urology

Real-world data underline that only a minority of patients complete the recommended 4–6 chemotherapy cycles.

Predictive biomarkers are expected to play a pivotal role in further enhancing treatment outcomes as they can identify patients at higher risk of recurrence.

A recent clinical trial explored the efficacy of combining pembrolizumab, an anti-PD-1 immunotherapy, with standard platinum-based chemotherapy.

Postoperative neurogenic bladder significantly impacts patients’ quality of life, necessitating prolonged catheter use in up to 16% of cases.

Recent data shows a significant increase in germline genetic testing for prostate cancer, with a notable rise in urologist involvement.

A recent study examining prostate cancer treatments within the US Department of Veterans Affairs health system has raised concerns about overtreatment, particularly among men with limited life expectancy.

The study revealed that patients treated for prostate cancer, particularly with radiotherapy, have an elevated risk of developing several severe complications.

New research has revealed potential links between agricultural pesticide exposure and higher rates of prostate cancer among men in the USA.